The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt(®)) as a primary therapy in patients with open-angle glaucoma or ocular hypertension

Survey of Ophthalmology

Volumn 44, Issue SUPPL. 2, 2000, Pages S155-S162

  Sall, Kenneth ^a  

^a NONE   (United States)

Author keywords

Azopt( ); Brinzolamide; Carbonic anhydrase inhibitor; Dorzolamide; Glaucoma; Ocular hypertension; Open angle glaucoma; Primary therapy

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EYE IRRITATION; FEMALE; HEADACHE; HUMAN; HYPEREMIA; INFECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VISUAL IMPAIRMENT;

EID: 0034056845     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(99)00107-1     Document Type: Article

References (12)

1. Camras C, Brinzolamide Primary Therapy Study Group: A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1.0% compared to TID-doses dorzolamide 2.0% and BID-dosed timolol 0.5% (abstract). Invest Ophthalmol Vis Sci 38(suppl):S560, 1997
2. Donohue EK, WilenskyJT: Trusopt, a topical carbonic anhydrase inhibitor. J Glaucoma 5:68-74, 1996
3. Epstein DL, Grant M: Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 95:1378-82, 1977
4. Lichter PR, Newman LP, Wheeler NC, Beall OV: Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol 85:495-502, 1978
5. ®), a new topical carbonic anhydrase inhibitor, in patients with open angle glaucoma and ocular hypertension (abstract). Invest Ophthalmol Vis Sci 39(suppl 4):S199, 1998
6. Shin DH, Brinzolamide Adjunctive Study Group: A triple-masked, placebo-controlled, adjunctive study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5% (abstract). Invest Ophthalmol Vis Sci 38(Suppl):S559, 1997
7. ®) in patients with primary open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 44(suppl 2):S163-8, 2000
8. ®), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol (in press)
9. ®). Surv Ophthalmol 44(suppl 2):S147-53, 2000
10. Silver L, Brinzolamide Comfort Study Group: The ocular comfort of brinzolamide 1.0% ophthalmic suspension compared to dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol 44(suppl 2):S141-5, 2000
11. Stewart R, Brinzolamide Comfort Study Group: The ocular comfort of a TID-d osed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci 38(suppl):S559, 1997
12. Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group: A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 122:183-94, 1996